Arcus Biosciences, Inc.: directors' dealings · United States · SEC (Form 4)

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. (NYSE: RCUS) is a clinical-stage biopharmaceutical company headquartered in Hayward, California, in the United States. Founded in 2015, Arcus was built around deep discovery capabilities and a strategy centered on rational combination therapies with the aim of developing best-in-class medicines, primarily in oncology. Unlike a commercial-stage pharmaceutical company, Arcus is still a pipeline-driven story: for investors, the key value drivers are clinical data, regulatory progress, partnership economics, and the company’s ability to convert experimental assets into approved therapies. Arcus’ core business is cancer drug development. Its leading programs include domvanalimab, an Fc-silent anti-TIGIT antibody being studied together with zimberelimab, an anti-PD-1 antibody; casdatifan, a HIF-2α inhibitor focused on clear cell renal cell carcinoma; and quemliclustat, a small-molecule CD73 inhibitor being evaluated in pancreatic cancer. The company has also expanded into inflammation and immunology, with preclinical programs targeting MRGPRX2, TNF, CCR6, CD89 and CD40L. This broader portfolio matters strategically: it diversifies scientific risk beyond a single mechanism, but it also increases operational complexity and development spending. From a competitive standpoint, Arcus operates in one of the most crowded segments of biotech, where large pharmaceutical groups and better-capitalized peers compete across the same therapeutic pathways and tumor types. Arcus’ differentiation lies in its combination-therapy design philosophy, its chemistry and translational expertise, and its partnership model. Collaborations with Gilead and AstraZeneca provide external validation, development support, and the potential for shared future commercialization, while also implying that some economics are shared. For investors, Arcus should be viewed as a high-upside, high-risk clinical oncology platform rather than a stable earnings compounder. Geographically, the company’s operational base is in California, but its footprint is global through clinical trials and regional collaboration rights. Taiho holds rights in Japan and certain other Asian territories for selected programs, while AstraZeneca is involved in the PACIFIC-8 phase 3 study in unresectable stage III non-small cell lung cancer. Recent highlights in 2025 and 2026 have centered on casdatifan’s ongoing development, pipeline prioritization, and continued execution in late-stage trials. Arcus has also accessed capital through equity offerings, which is important for investors to monitor given the need to fund an expensive and lengthy clinical development cycle on the NYSE in the United States.